Peptide for inducing regeneration of tissue and use thereof

Inventors

Tamai, Katsuto • Yamazaki, Takehiko • Kanezaki, Tsutomu • Sakurai, Shigeru • NOGUCHI, Yukiko • Endo, Mayumi • Hamabuchi, Natsumi • Naito, Kana

Assignees

StemRIM Inc • The University of Osaka

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10550165-B2

Patent

Publication Date

2020-02-04

Expiration Date


Abstract

(Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body.(Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFRα-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFRα-positive cells.

Core Innovation

The disclosure relates to HMGB1-derived synthetic peptides that have an activity of stimulating migration of a cell. The peptides are selected from specific portions of an HMGB1 protein of the amino acid sequence of SEQ ID NO: 1 and are defined by whole or part amino acid sequence positions within SEQ ID NO: 1, including selected position windows and included subsequences.

The disclosure identifies peptide activity linked to specific HMGB1 fragment regions and subregions, including activity in 1–84, 1–44, and 45–84, with further refinement around positions 11–25 and within 45–74, 55–84, and 85–169 windows. The document also reports that shorter C-terminus fragments can show enhanced activity and that a C-terminal acidic tail suppresses activity.

Stimulation of migration is associated with recruitment of PDGFRα-positive cells, including bone-marrow mesenchymal stem cells and skin fibroblasts. In vivo administration of a synthetic peptide 1–44 is reported to increase PDGFRα+CD44+ cells in blood and to reduce cerebral infarct size in a rat stroke model, and skin-flap experiments suggest improved wound outcomes.

Claims Coverage

The provided independent claim coverage centers on HMGB1-derived peptides with activity of stimulating migration of a cell. The inventive features combine peptide identity from SEQ ID NO: 1 with specified position windows and included subsequences that maintain the stated activity.

HMGB1-derived migration-stimulating peptides from SEQ ID NO: 1

A peptide selected from HMGB1 protein sequences of SEQ ID NO: 1 that has an activity of stimulating migration of a cell, wherein the peptide consists of the whole or part of the amino acid sequence of specified position ranges in SEQ ID NO: 1 and comprises at least one of the listed amino acid sequences in those ranges.

Position-window peptide selections across N-terminal, middle, and extended regions

A peptide consisting of the whole or part of amino acid sequence positions 1 to 52, 1 to 25 or 17 to 44, 1 to 205 with 89 to 195, 45 to 215 with an included subsequence, or any of the listed peptide sequences consisting of ranges including 1–44, 1–70, 1–84, 1–170, 1–185, 1–195, 2–44, 2–70, 2–84, 2–170, 2–185, 2–195, 17–25, 45–84, 85–169, 89–185, 89–195, and 93–215, all in the context of stimulating migration activity.

Across the provided independent claim, coverage is centered on HMGB1-derived peptides defined by SEQ ID NO: 1 and specified amino acid position windows and subsequences that yield an activity of stimulating migration of a cell. The claim’s enumerated alternatives define multiple permissible length ranges and specific included subsequences.

Stated Advantages

Stimulating migration of a cell.

Stimulating migration/mobilization of PDGFRα-positive cells.

Mobilizing bone-marrow cells to peripheral blood.

Regenerating tissues.

Increasing PDGFRα+CD44+ cells in blood after intravenous administration of a synthetic peptide 1–44.

Reducing cerebral infarct size in a rat stroke model.

Suggesting improved wound outcomes in skin-flap experiments.

Increases migration-promoting potency and stability/production feasibility by truncation or removal of the C-terminal acidic tail.

Improves skin-wound outcomes in rat models with reduced necrosis/ulceration compared with longer fragments or full-length HMGB1.

Reduces infarct expansion versus a negative control in a rat middle cerebral artery thread occlusion stroke model when peptide (1-44) is used.

Reduced dosing due to higher activity per mass/mole as stated in the document.

Reduced endotoxin (LPS) affinity as stated in the document.

Safer, simpler intravenous administration for regeneration, including cerebral infarction, as stated in the document.

Documented Applications

Use of HMGB1-derived peptides for tissue regeneration via stimulating migration/mobilization of PDGFRα-positive cells, including bone-marrow mesenchymal stem cells and skin fibroblasts.

Mobilization of bone-marrow cells to peripheral blood.

A rat stroke model context where intravenous administration of a synthetic peptide 1–44 reduces cerebral infarct lesion size and increases PDGFRα+CD44+ cells in blood.

Skin-flap experiments suggesting improved wound outcomes.

Compositions for stimulating migration, mobilizing bone-marrow cells to peripheral blood, and regenerating tissues, including peptide-only, cell-secreting, and vector-based forms.

Regeneration and tissue repair outcomes, including skin-wound outcomes with reduced necrosis/ulceration in rat models.

Treatment-related effect in cerebral ischemia, described via a rat middle cerebral artery thread occlusion stroke model where peptide reduces infarct expansion.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.